Journal Basic Info

  • Impact Factor: 1.809**
  • H-Index: 6
  • ISSN: 2474-1655
  • DOI: 10.25107/2474-1655
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Orthopedic Sugery
  •  Obstetrics and Gynecology
  •  Endocrinology
  •  Nuclear Medicine
  •  Asthma
  •  Nursing
  •  Anesthesiology and Pain Medicine
  •  Veterinary Sciences


Citation: Ann Clin Case Rep. 2022;7(1):2247.DOI: 10.25107/2474-1655.2247

Successful Treatment of Acinetobacter baumannii Infection in Burn Child with Avibactam/Sulbactam: A Case Report

Afaf H Ghunaim1,2, Ahmad M Alghamdi1,2, Erada M Alghamdi2,3 and Mona Aldabbagh1,2,4*

1Department of Pediatrics, King Abdulaziz Medical City, Saudi Arabia
2King Abdullah International Medical Research Centre, Saudi Arabia
3Department of Emergency Medicine, King Abdulaziz Medical City, Saudi Arabia
4King Saud bin Abdulaziz University for Health Sciences, Saudi Arabia

*Correspondance to: Mona Aldabbagh 

 PDF  Full Text Case Report | Open Access


Infection with multi-drug resistant bacteria is an uprising clinical problem that requires the development of new antimicrobial agents. Sulbactam/avibactam increases sulbactam activity against multi-drug resistant Acinetobacter baumannii in vitro; however, it has not been tested clinically yet. Moreover, data about its use in children is limited. A 29-month-old boy was referred with a 40% burn. The patient was on colistin and tigecycline for A. baumannii wound infection. Meropenem was added for Serratia marcescens septicemia. However, repeated tissue culture revealed MDR A. baumannii, which was only sensitive to trimethoprim-sulfamethoxazole (bactrim). The patient had meropenem infusion in addition to Bactrim for three weeks. Unfortunately, the meropenem and bactrim were halted because of treatment failure. Treatment was changed to ceftazidime/avibactam and aztreonam. The patient deteriorated clinically after two days of this regimen; therefore, colistin was added empirically. After one week of persistent fever and elevated inflammatory markers, ceftazidime/avibactam and ampicillin/sulbactam were started. The fever subsided in 48 h, and the inflammatory markers trended down with laboratory evidence of organism clearance after two weeks. This case showed that avibactam/sulbactam could be an option for managing MDR A. baumannii nosocomial infection in children.


Cite the Article:

Ghunaim AH, Alghamdi AM, Alghamdi EM, Aldabbagh M. Successful Treatment of Acinetobacter baumannii Infection in Burn Child with Avibactam/ Sulbactam: A Case Report. Ann Clin Case Rep. 2022; 7: 2247.

Search Our Journal

Journal Indexed In

Articles in PubMed

Does Autoimmunity have a Role in Myoclonic Astatic Epilepsy? A Case Report of Voltage Gated Potassium Channel Mediated Seizures
 PubMed  PMC  PDF  Full Text
Tocotrienols: Exciting Biological and Pharmacological Properties of Tocotrienols and Naturally Occurring Compounds, Part II
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Clinical Evidence for the Use of Methylone in the Treatment of PTSD: A Case Series with Long-Term Follow- Up
 Abstract  PDF  Full Text
A Drug-Free, Digital, Self-Management Tool for Chronic Pain Patients Powered by Artificial Intelligence – A Pilot Trial
 Abstract  PDF  Full Text
View More...